Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§

Juliane Winkelmann, Richard Allen, Birgit Högl, Yuichi Inoue, Wolfgang Oertel, Aaro V. Salminen, John W. Winkelman, Claudia Trenkwalder, Cristina Sampaio

Research output: Contribution to journalReview article

Abstract

The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious. Intravenous ferric carboxymaltose and pneumatic compression devices are considered likely efficacious in idiopathic restless legs syndrome. Bupropion and clonidine were reviewed, but the lack of data determined a rating of insufficient evidence for efficacy. The following interventions continue to be considered efficacious as in 2008: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Bromocriptine, oxycodone, carbamazepine, and valproic acid are considered likely efficacious. Oral iron is nonefficacious in iron-sufficient subjects, but its benefit for patients with low peripheral iron status has not been adequately evaluated. Restless legs syndrome augmentation has been identified as a significant long-term treatment complication for pramipexole more than pregabalin and possibly for all dopaminergic agents more than α2δ ligands. Therefore, special monitoring for augmentation is required for all dopaminergic medications as well as tramadol. Other drugs also require special safety monitoring: cabergoline, pergolide, oxycodone, methadone, tramadol, carbamazepine, and valproic acid. Finally, we also highlighted gaps and needs for future clinical research and studies of restless legs syndrome.

Original languageEnglish (US)
Pages (from-to)1077-1091
Number of pages15
JournalMovement Disorders
Volume33
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Restless Legs Syndrome
Oxycodone
Pergolide
Tramadol
Iron
Carbamazepine
Valproic Acid
Bupropion
Dopamine Agents
Bromocriptine
Evidence-Based Medicine
Methadone
Clonidine
Levodopa
Therapeutics
Naloxone
Randomized Controlled Trials
Ligands
Safety
Equipment and Supplies

Keywords

  • augmentation
  • evidence-based medicine
  • guidelines
  • MDS recommendations
  • restless legs syndrome (RLS)
  • therapy
  • treatment

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Treatment of restless legs syndrome : Evidence-based review and implications for clinical practice (Revised 2017)§. / Winkelmann, Juliane; Allen, Richard; Högl, Birgit; Inoue, Yuichi; Oertel, Wolfgang; Salminen, Aaro V.; Winkelman, John W.; Trenkwalder, Claudia; Sampaio, Cristina.

In: Movement Disorders, Vol. 33, No. 7, 01.07.2018, p. 1077-1091.

Research output: Contribution to journalReview article

Winkelmann, J, Allen, R, Högl, B, Inoue, Y, Oertel, W, Salminen, AV, Winkelman, JW, Trenkwalder, C & Sampaio, C 2018, 'Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§', Movement Disorders, vol. 33, no. 7, pp. 1077-1091. https://doi.org/10.1002/mds.27260
Winkelmann, Juliane ; Allen, Richard ; Högl, Birgit ; Inoue, Yuichi ; Oertel, Wolfgang ; Salminen, Aaro V. ; Winkelman, John W. ; Trenkwalder, Claudia ; Sampaio, Cristina. / Treatment of restless legs syndrome : Evidence-based review and implications for clinical practice (Revised 2017)§. In: Movement Disorders. 2018 ; Vol. 33, No. 7. pp. 1077-1091.
@article{bb779c849fe241cc8d0aa4e4ac21064f,
title = "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§",
abstract = "The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious. Intravenous ferric carboxymaltose and pneumatic compression devices are considered likely efficacious in idiopathic restless legs syndrome. Bupropion and clonidine were reviewed, but the lack of data determined a rating of insufficient evidence for efficacy. The following interventions continue to be considered efficacious as in 2008: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Bromocriptine, oxycodone, carbamazepine, and valproic acid are considered likely efficacious. Oral iron is nonefficacious in iron-sufficient subjects, but its benefit for patients with low peripheral iron status has not been adequately evaluated. Restless legs syndrome augmentation has been identified as a significant long-term treatment complication for pramipexole more than pregabalin and possibly for all dopaminergic agents more than α2δ ligands. Therefore, special monitoring for augmentation is required for all dopaminergic medications as well as tramadol. Other drugs also require special safety monitoring: cabergoline, pergolide, oxycodone, methadone, tramadol, carbamazepine, and valproic acid. Finally, we also highlighted gaps and needs for future clinical research and studies of restless legs syndrome.",
keywords = "augmentation, evidence-based medicine, guidelines, MDS recommendations, restless legs syndrome (RLS), therapy, treatment",
author = "Juliane Winkelmann and Richard Allen and Birgit H{\"o}gl and Yuichi Inoue and Wolfgang Oertel and Salminen, {Aaro V.} and Winkelman, {John W.} and Claudia Trenkwalder and Cristina Sampaio",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/mds.27260",
language = "English (US)",
volume = "33",
pages = "1077--1091",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Treatment of restless legs syndrome

T2 - Evidence-based review and implications for clinical practice (Revised 2017)§

AU - Winkelmann, Juliane

AU - Allen, Richard

AU - Högl, Birgit

AU - Inoue, Yuichi

AU - Oertel, Wolfgang

AU - Salminen, Aaro V.

AU - Winkelman, John W.

AU - Trenkwalder, Claudia

AU - Sampaio, Cristina

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious. Intravenous ferric carboxymaltose and pneumatic compression devices are considered likely efficacious in idiopathic restless legs syndrome. Bupropion and clonidine were reviewed, but the lack of data determined a rating of insufficient evidence for efficacy. The following interventions continue to be considered efficacious as in 2008: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Bromocriptine, oxycodone, carbamazepine, and valproic acid are considered likely efficacious. Oral iron is nonefficacious in iron-sufficient subjects, but its benefit for patients with low peripheral iron status has not been adequately evaluated. Restless legs syndrome augmentation has been identified as a significant long-term treatment complication for pramipexole more than pregabalin and possibly for all dopaminergic agents more than α2δ ligands. Therefore, special monitoring for augmentation is required for all dopaminergic medications as well as tramadol. Other drugs also require special safety monitoring: cabergoline, pergolide, oxycodone, methadone, tramadol, carbamazepine, and valproic acid. Finally, we also highlighted gaps and needs for future clinical research and studies of restless legs syndrome.

AB - The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious. Intravenous ferric carboxymaltose and pneumatic compression devices are considered likely efficacious in idiopathic restless legs syndrome. Bupropion and clonidine were reviewed, but the lack of data determined a rating of insufficient evidence for efficacy. The following interventions continue to be considered efficacious as in 2008: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Bromocriptine, oxycodone, carbamazepine, and valproic acid are considered likely efficacious. Oral iron is nonefficacious in iron-sufficient subjects, but its benefit for patients with low peripheral iron status has not been adequately evaluated. Restless legs syndrome augmentation has been identified as a significant long-term treatment complication for pramipexole more than pregabalin and possibly for all dopaminergic agents more than α2δ ligands. Therefore, special monitoring for augmentation is required for all dopaminergic medications as well as tramadol. Other drugs also require special safety monitoring: cabergoline, pergolide, oxycodone, methadone, tramadol, carbamazepine, and valproic acid. Finally, we also highlighted gaps and needs for future clinical research and studies of restless legs syndrome.

KW - augmentation

KW - evidence-based medicine

KW - guidelines

KW - MDS recommendations

KW - restless legs syndrome (RLS)

KW - therapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85051365468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051365468&partnerID=8YFLogxK

U2 - 10.1002/mds.27260

DO - 10.1002/mds.27260

M3 - Review article

C2 - 29756335

AN - SCOPUS:85051365468

VL - 33

SP - 1077

EP - 1091

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -